A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
Clinical trial NCT06003673 · UNKNOWN
Trial details
- NCT number
- NCT06003673
- Sponsor
- First Affiliated Hospital of Fujian Medical University
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-01
- Primary completion
- 2024-07-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.